Name: BNR Income Statement - Burning Rock Biotech Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

BNR - Burning Rock Biotech Ltd.

USD | NASDAQ | Healthcare

BNR Income Statement - Burning Rock Biotech Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues
Revenues	77.2	70.7	75.7	81.7	79.7	65.9
Cost of Revenue	19.5	21.0	24.5	26.6	22.6	17.8
Gross Profit	57.6	49.6	51.2	55.1	57.1	48.1
Operating Expenses
Research & Development	23.8	31.8	48.9	61.2	57.7	40.5
Selling General & Administrative	-	-	-	-	-	-
Operating Income
Operating Income	(7.8)	(49.0)	(94.3)	(142.1)	(125.1)	(63.2)
Non-Operating
Interest Income	1.2	1.7	2.5	1.4	0.5	0.9
Interest Expense	-	-	-	-	0.2	0.1
Income From Equity Investments
Tax & Net
Income Tax Expense	0.2	0.8	0.3	0.3	0.1	0.0
Net Income From Continuing Ops	(7.9)	(47.5)	(92.1)	(140.8)	(125.0)	(62.4)
Net Income From Discontinued Ops
Per Share
EPS Basic	-	-	-	-	-	-
EPS Diluted	-	-	-	-	-	-
Shares Basic	-
Supplementary Data
EBITDA	(4.7)	(41.8)	(75.5)	(124.2)	(117.6)	(58.1)
EBIT	(7.8)	(49.0)	(94.3)	(142.1)	(125.1)	(63.2)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)